drugset / Trial / NCT00816517

Use of Botulinum Toxin to Treat Psoriasis

NCT00816517

Phase 1 Completed 8 enrolled University of Minnesota Allergan · collab
NaSingle-groupOpen-labelTreatment

Summary

Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoriasis. Botulinum toxin has been shown to have an effect on inhibiting neurogenic inflammation. Recently, it was reported that patients who suffered from dystonia and had concomitant psoriasis, when treated with botulinum toxin for dystonia noted a dramatic improvement of their psoriatic lesions. This pilot study will determine the safety and efficacy of botulinum toxin in the management of psoriasis vulgaris.

Timeline

Start
2009-01
Primary completion
2015-06
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 35 iu Other
Subject Botulinum toxin type A Protein / enzyme biologic 100 iu Other

Indications